Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27848461 | 0.84 | KMT2A (0.55) | KMT2AMEN1MAP4K4POLBCYP11B1 | |
| SCHEMBL343986 | 0.82 | NOTUM (0.61) | KMT2AMEN1POLBCYP11B1CYP11B2 | |
| SCHEMBL2158739 | 0.79 | KMT2A (0.75) | KMT2AMEN1MAP4K4POLBCYP11B1 | |
| SCHEMBL27712073 | 0.78 | KMT2A (0.59) | KMT2AMEN1MAP4K4POLBCYP11B1 | |
| SCHEMBL14620819 | 0.78 | NOTUM (0.56) | KMT2AMEN1POLBCYP11B1CYP11B2 | |
| SCHEMBL10408548 | 0.75 | ALDH1A1 (0.56) | PFKFB3ALDH1A1HSD17B10TDP1LMNA | |
| SCHEMBL18394452 | 0.75 | MEN1 (0.64) | KMT2AMEN1MAP4K4CYP11B1CYP11B2 | |
| SCHEMBL5270396 | 0.74 | MEN1 (0.58) | KMT2AMEN1MAP4K4CYP11B1CYP11B2 | |
| SCHEMBL29808221 | 0.73 | KMT2A (0.66) | KMT2AMEN1MAP4K4POLBCYP11B1 | |
| SCHEMBL4249325 | 0.72 | MEN1 (0.55) | KMT2AMEN1MAP4K4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1786813-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | KMT2A 1169/4885MEN1 3491/4885MAP4K4 1631/4885 |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | C5, C1R, C1QBP | KMT2A 3595/4885MEN1 2106/4885MAP4K4 2150/4885 |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | C5, C1QBP, C1R | KMT2A 3547/4885MEN1 2090/4885MAP4K4 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.